Article
Oncology
Dongsheng Yue, Juanjuan Qian, Zhipeng Chen, Bin Zhang, Peng Chen, Lei Zhang, Jingjing Li, Henghui Zhang, Changli Wang
Summary: This study reported a case of ROS1-rearranged lung adenocarcinoma patient who responded well to lorlatinib, suggesting that lorlatinib may be a better choice than immunotherapy in second-line setting for patients with similar genomic characteristics. The research found that the response of patients to treatment during immunotherapy is related to changes in immune factors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Nanoscience & Nanotechnology
Lili Chen, Wenpeng Zhou, Ziyin Ye, Xiaoming Zhong, Jianwen Zhou, Shaohong Chen, Wei Liu, Yu Sun, Lijuan Ren, Xiaojun Tan, Ji Cui, Zhirong Zeng, Weiling He, Zunfu Ke
Summary: Based on the assessment of CTCs, this study found that CEP8 and CK-positive CTCs have the potential to improve the risk stratification of stage II CRC patients. In the subgroup with clinical high risk, the number of preoperative CTCs is associated with treatment outcome. Moreover, if postoperative CTC levels remain above 4 for more than three consecutive time points, the recurrence rate is 100%.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Article
Chemistry, Medicinal
Chaithanya Chelakkot, Hobin Yang, Young Kee Shin
Summary: Shedding cancer cells from the primary site or bone marrow into the circulatory system and their subsequent formation of secondary metastatic lesions is a key feature of invasive cancers. Circulating tumor cells (CTCs), found either as single cells or clusters, carry valuable information and have the potential to predict cancer prognosis, progression, and guide tailored therapies.
Article
Chemistry, Multidisciplinary
Liang Chen, Shihua Luo, Zhilei Ge, Chunhai Fan, Yang Yang, Qian Li, Yuanqing Zhang
Summary: The research team established an unbiased enrichment method for CTCs using a DNAzyme-catalyzed strategy based on DNA framework. This method has higher enrichment efficiency and lower bias compared to traditional methods, providing a new solution for CTC-based cancer diagnostics.
Review
Biochemistry & Molecular Biology
Monika Vidlarova, Alona Rehulkova, Pavel Stejskal, Andrea Prokopova, Hanus Slavik, Marian Hajduch, Josef Srovnal
Summary: Circulating tumor cells (CTCs) are released from primary tumors and have been identified as a negative prognostic factor for survival in many types of cancer. They also provide valuable insights into tumor progression, cell senescence, and cancer dormancy. Various methods with different specificity, utility, costs, and sensitivity have been developed for isolating and characterizing CTCs, with novel techniques being developed to overcome limitations of existing methods. This literature review describes the current and emerging methods for enriching, detecting, isolating, and characterizing CTCs.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Amanda J. W. Gibson, Adrian Box, Winson Y. Cheung, Michelle L. Dean, Anifat A. Elegbede, Desiree Hao, Aliyah Pabani, Randeep Sangha, Dafydd Gwyn Bebb
Summary: This retrospective review focused on the use, safety, and effectiveness of crizotinib in treating ROS1-rearranged NSCLC patients in a real-world Canadian clinical cohort. The study found that crizotinib was well-tolerated and effective, but its effectiveness was lower than that observed in clinical trials. It was also observed that prior systemic anti-cancer therapy, particularly platin-pemetrexed, showed good effectiveness, while immune checkpoint inhibitors had poor effectiveness. Overall, timely identification of ROS1-rearrangements and initiation of targeted therapies appeared important for maximizing outcomes in this patient population.
Article
Genetics & Heredity
Miaomiao Weng, Hui Xie, Mingjie Zheng, Xinwen Hou, Shui Wang, Yue Huang
Summary: CD161 is downregulated in breast cancer and its low expression is associated with poor prognosis. It is involved in immune response and various tumor-related pathways in breast cancer development.
FRONTIERS IN GENETICS
(2022)
Article
Oncology
Danila Comandini, Fabio Catalano, Massimiliano Grassi, Guido Pesola, Rossella Bertulli, Antonio Guadagno, Bruno Spina, Matteo Mascherini, Franco De Cian, Federico Pistoia, Sara Elena Rebuzzi
Summary: Inflammatory myofibroblastic tumor (IMT) is a rare subtype of sarcoma often associated with chromosomal rearrangements such as ALK and ROS1 kinase fusions. Treatment options for advanced IMTs are limited, but tyrosine kinase inhibitors have shown promising efficacy in patients with targetable genomic alterations. Resectable tumors are typically treated with radical surgery, while unresectable IMT patients should be evaluated for chromosomal abnormalities and gene mutations for targeted therapy and clinical trials.
FRONTIERS IN ONCOLOGY
(2021)
Review
Medicine, General & Internal
Marta Lukaszewicz-Zajac, Barbara Mroczko
Summary: The global burden of colorectal cancer is expected to increase in the coming years. Inflammatory mediators show promise as novel biomarkers for colorectal cancer, but further validation of their sensitivity and specificity is required.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Hee Seung Lee, Eun Hye Jung, Hyejung Shin, Chan Su Park, Soo Been Park, Dawoon E. Jung, Galam Leem, So Jung Kim, Jung Hyun Jo, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Si Young Song
Summary: The study found that CTCs can serve as predictive biomarkers of clinical outcomes in patients with PDAC. In particular, changes in the total CTC count and vimentin-positive CTCs were associated with chemotherapy response.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Huikai Zhang, Fanen Yuan, Yangzhi Qi, Baohui Liu, Qianxue Chen
Summary: Liquid biopsy has been applied in various cancers but little progress has been made in validating circulating biomarkers for brain malignancies. Data on circulating tumor cells in glioma are limited, and their application as a biomarker has just begun.
FRONTIERS IN ONCOLOGY
(2021)
Review
Cell Biology
Maurizio Capuozzo, Francesco Ferrara, Mariachiara Santorsola, Andrea Zovi, Alessandro Ottaiano
Summary: This article reviews the role of circulating tumor cells (CTCs) in solid tumors, highlighting their importance in predicting clinical outcomes and guiding prognosis. The article also discusses the recent advancements and challenges in CTC detection methods, as well as the significance of integrating CTC-based liquid biopsies into clinical practice.
Review
Genetics & Heredity
Lemei Zhu, Ran Xu, Leilei Yang, Wei Shi, Yuan Zhang, Juan Liu, Xi Li, Jun Zhou, Pingping Bing
Summary: Minimal residual disease (MRD) refers to a small number of residual tumor cells during or after treatment, which can be monitored and predicted using ctDNA detection. This review summarizes the main methods of ctDNA detection and its application in lung, breast, and colon cancer, among others.
FRONTIERS IN GENETICS
(2023)
Article
Oncology
Jie Zhang, Yang Hong, Liang Wang, Weiheng Hu, Guangming Tian, Di Wu, Yang Wang, Ling Dai, Ziran Zhang, Yue Yang, Jian Fang
Summary: This study aimed to detect and describe the distribution characteristics of circulating tumor cells (CTCs) and circulating tumor-derived endothelial cells (CTECs) in patients with advanced lung cancer, and explore the correlation between CTC/CTEC subtypes and novel prognostic biomarkers. CTCs and CTECs derived from 52 patients with advanced lung cancer were identified using the subtraction enrichment-immunofluorescence in situ hybridization (SE-iFISH) system.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Mahmoud Labib, Shana O. Kelley
Summary: Analysis of circulating tumor cells provides valuable insights in precision oncology, revealing associations between CTCs molecular profiles and tumor response to therapy. However, current limitations hinder the widespread clinical implementation of CTCs, suggesting the need for further research and advanced technologies.
MOLECULAR ONCOLOGY
(2021)
Article
Genetics & Heredity
Saioa Lopez, Emilia L. Lim, Stuart Horswell, Kerstin Haase, Ariana Huebner, Michelle Dietzen, Thanos P. Mourikis, Thomas B. K. Watkins, Andrew Rowan, Sally M. Dewhurst, Nicolai J. Birkbak, Gareth A. Wilson, Peter Van Loo, Mariam Jamal-Hanjani, Charles Swanton, Nicholas McGranahan
Review
Oncology
H. Adderley, F. H. Blackhall, C. R. Lindsay
Summary: Treatment stratification in stage IV NSCLC is guided by oncogene driver mutations, with a focus on small molecule therapy and immune checkpoint inhibitors. Proper sequencing of therapy is crucial for safe and effective treatment delivery.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Oncology
Victoria Dunnett-Kane, Pantelis Nicola, Fiona Blackhall, Colin Lindsay
Summary: KRAS is a commonly mutated gene in cancer, but efforts to create direct inhibitors have largely failed until recent subtype specific inhibitors have shown promise. G12C inhibitors have entered clinical trials and shown early evidence of efficacy in patients, but there are concerns about potential drug resistance.
Editorial Material
Biochemistry & Molecular Biology
Mathias T. Rosenfeldt, Jim O'Prey, Colin R. Lindsay, Colin Nixon, Sabine Roth, Owen J. Sansom, Kevin M. Ryan
CELL DEATH AND DIFFERENTIATION
(2021)
Article
Oncology
Victoria Foy, Colin R. Lindsay, Alexandra Carmel, Fabiola Fernandez-Gutierrez, Matthew G. Krebs, Lynsey Priest, Mathew Carter, Harry J. M. Groen, T. Jeroen N. Hiltermann, Antonella de Luca, Francoise Farace, Benjamin Besse, Leon Terstappen, Elisabetta Rossi, Alessandro Morabito, Francesco Perrone, Andrew Renehan, Corinne Faivre-Finn, Nicola Normanno, Caroline Dive, Fiona Blackhall, Stefan Michiels
Summary: The number of circulating tumor cells (CTC) is an important independent prognostic factor in patients with small cell lung cancer. It can be used as a continuous variable or classified into two groups (>=15 or >=50) to evaluate patient prognosis. Incorporating CTC counts as a continuous variable improves clinic-pathological prognostic models.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Cell Biology
Nadira Narine, Andrew Wallace, Jonathan Dore, Simon O'Leary-Jackson, Haider Al Najjar, Simon Bailey, Kashif Khan, Benjamin Teng, Muhammad Qasim, David Shelton, Miles Holbrook, Salma Abbasi, Matthew Carter, Luciane Irion, Samer Al-Habba, Colin Lindsay, Fiona Blackhall, Durgesh Rana
Summary: Immunohistochemistry (IHC) for ROS1 protein product on cytology cell blocks and small biopsy samples is a promising screening method for assessing eligibility for TKI treatment, with good negative predictive value, faster turnaround time, and cost effectiveness. Positive and indeterminate cases can be confirmed by FISH or NGS.
Editorial Material
Oncology
Jordi Remon, Lizza E. L. Hendriks, Benjamin Besse
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Julie Delorme, Valentin Charvet, Muriel Wartelle, Francois Lion, Bruno Thuillier, Sandrine Mercier, Jean-Charles Soria, Mikael Azoulay, Benjamin Besse, Christophe Massard, Antoine Hollebecque, Loic Verlingue
Summary: The study aimed to predict successful completion of screening and dose-limiting toxicity period in early-phase oncology trials using machine learning. By transforming consultation reports into semantic vectors and clustering them, a model was trained to achieve high performance in predicting patient outcomes.
JCO CLINICAL CANCER INFORMATICS
(2021)
Review
Oncology
Colin R. Lindsay, Marina C. Garassino, Ernest Nadal, Katarina Ohrling, Matthias Scheffler, Julien Mazieres
Summary: KRAS mutations play a significant role in NSCLC, with novel direct KRAS inhibitors showing promising results as monotherapy or in combination with targeted therapies, chemotherapy, and immunotherapy.
Article
Economics
Valentine Grumberg, Christos Chouaid, Francois-Emery Cotte, Baptiste Jouaneton, Ronan Jolivel, Anne-Francoise Gaudin, Dorothee Reynaud, Jean-Baptiste Assie, Isabelle Borget
Summary: Healthcare resource utilization and costs for patients with advanced non-small cell lung cancer (aNSCLC) treated with nivolumab decreased over time.
JOURNAL OF MEDICAL ECONOMICS
(2022)
Article
Oncology
Alexander Drilon, Joshua C. Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M. Gadgeel, D. Ross Camidge, Anthonie J. van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S. Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R. Soglia, Nancy E. Kohl, James R. Porter, Matthew D. Shair, Viola Zhu, Monika A. Davare, Aaron N. Hata, Henry E. Pelish, Jessica J. Lin
Article
Health Care Sciences & Services
Amelia Payne, Ashley Horne, Neil Bayman, Fiona Blackhall, Layla Bostock, Clara Chan, Joanna Coote, Marie Eaton, Jacqueline Fenemore, Fabio Gomes, Emma Halkyard, Margaret Harris, Colin Lindsay, Delyth McEntee, Hilary Neal, Laura Pemberton, Hamid Sheikh, David Woolf, James Price, Janelle Yorke, Corinne Faivre-Finn
Summary: This study investigates the experiences of patients and clinicians using the ePROMs service at Christie NHS Foundation Trust in the UK. The results show that the use of ePROMs improves communication and increases patient involvement in their care, as reported by both patients and clinicians. This study demonstrates the acceptability and positive impact of incorporating ePROMs into routine cancer care.
JOURNAL OF PATIENT-REPORTED OUTCOMES
(2023)
Editorial Material
Oncology
Marco Tagliamento, Jordi Remon, David Planchard, Benjamin Besse
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Health Care Sciences & Services
Tess Martin, Alessandra Guercio, Helene Besseau, Laure Huot, Pascale Guerre, Jamal Atfeh, Laurent Piazza, Judith Pineau, Brigitte Sabatier, Isabelle Borget, Nicolas Martelli
Summary: A national survey was conducted to assess the implementation of hospital-based health technology assessment (HB-HTA) in French hospitals and to identify its level of formalization.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
(2023)
Article
Oncology
Marguerite Kandel, Aurelie Bardet, Stephane Dalle, Clara Allayous, Laurent Mortier, Bernard Guillot, Caroline Dutriaux, Marie-Therese Leccia, Sophie Dalac, Henri Montaudie, Philippe Saiag, Delphine Legoupil, Florence Brunet-Possenti, Jean-Philippe Arnault, Julie De Quatrebarbes, Marie Beylot-Barry, Eve Maubec, Thierry Lesimple, Francois Aubin, Jean-Jacques Grob, Florence Granel-Brocard, Pierre-Emmanuel Stoebner, Alain Dupuy, Brigitte Dreno, Stefan Michiels, Celeste Lebbe, Isabelle Borget
Summary: This study conducted a cost-effectiveness analysis of different treatment sequences for advanced melanoma, finding certain sequences to be more effective and cost-efficient for BRAF-mutated and wild-type patients.